Building on this, we leverage our framework to identify a combination of the OLIG2 inhibitor, CT-179, with an anti-EGFR antibody-drug conjugate, Depatuxizumab Mafodotin (Depatux-M, ABT-414), which synergizes to increase survival in an orthotopic xenograft model of GBM. This evidence concerns the gene OLIG2 and glioblastoma.